Kazia Therapeutics Reports Preclinical Data on Paxalisib in Colorectal Cancer

Kazia Therapeutics has released preclinical findings indicating that its drug candidate, paxalisib, demonstrates potential in treating a specific type of colorectal cancer that is resistant to current immunotherapies. The study focused on MSS/pMMR colorectal cancer, a subtype known for its poor response to checkpoint inhibitor treatments.

In the preclinical model, paxalisib administered as a monotherapy led to a significant reduction in tumor burden. When combined with pembrolizumab, a checkpoint inhibitor, the therapeutic effect was further amplified, suggesting a synergistic benefit. The drug candidate was reportedly well-tolerated in both monotherapy and combination settings during these studies.

These results are significant as they address a critical unmet need in colorectal cancer treatment, where many patients with MSS/pMMR tumors do not benefit from existing immunotherapy options. The data suggests paxalisib could potentially overcome this resistance mechanism.

Kazia Therapeutics is currently evaluating further development pathways for paxalisib based on these promising preclinical outcomes. The company is preparing to advance its research and development efforts in this area.